JPMorgan Chase & Co. Sells 9,291 Shares of Xencor, Inc. (NASDAQ:XNCR)

JPMorgan Chase & Co. reduced its stake in Xencor, Inc. (NASDAQ:XNCR) by 7.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 121,063 shares of the biopharmaceutical company’s stock after selling 9,291 shares during the period. JPMorgan Chase & Co. owned 0.17% of Xencor worth $2,782,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. GAMMA Investing LLC grew its stake in Xencor by 31.0% in the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 508 shares during the last quarter. KBC Group NV boosted its holdings in shares of Xencor by 26.0% during the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 813 shares during the period. PNC Financial Services Group Inc. grew its position in shares of Xencor by 49.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 1,337 shares during the last quarter. Mutual of America Capital Management LLC bought a new position in shares of Xencor during the fourth quarter worth approximately $244,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in Xencor during the 4th quarter worth approximately $280,000.

Xencor Stock Up 0.5 %

XNCR stock opened at $10.65 on Wednesday. The company has a market cap of $750.42 million, a PE ratio of -3.33 and a beta of 0.90. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor, Inc. has a 52 week low of $7.16 and a 52 week high of $27.24. The business has a 50-day simple moving average of $12.10 and a 200 day simple moving average of $18.60.

Xencor (NASDAQ:XNCR) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.19. The company had revenue of $52.79 million during the quarter, compared to analysts’ expectations of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. Sell-side analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on XNCR. StockNews.com lowered Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th. Wells Fargo & Company decreased their price target on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Finally, William Blair began coverage on shares of Xencor in a research note on Monday. They issued an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Xencor presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.86.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.